Molecule docking into a neural receptor

GB-101 Synaptiva

Multimodal Cholinergic Neuromodulation

GB-101 is being developed as a multimodal cholinergic neuromodulator, designed around several complementary neurological mechanisms rather than a single molecular target.

Program
GB-101 Synaptiva
Class
Multimodal cholinergic neuromodulator
Stage
Preclinical / discovery research
Primary target
M1 muscarinic receptor
Modality
Small molecule

Mechanisms

Four mechanisms, one compound

  1. 01M1

    Primary Mechanism

    M1 Muscarinic Receptor Activation

    Designed to enhance cholinergic signaling pathways associated with cognition and neuronal activity.

    M1 is the dominant muscarinic subtype in cortex and hippocampus. Direct activation aims to reinforce postsynaptic cholinergic tone independently of the amount of acetylcholine available, with subtype selectivity over M2 and M3 as a central design constraint for peripheral tolerability.

  2. 02AChE

    Complementary Mechanism

    Controlled AChE Modulation

    Intended to prolong the activity of naturally released acetylcholine.

    Rather than maximal enzyme inhibition, the program targets a controlled, partial modulation profile — preserving physiological release patterns while extending signal duration, and limiting the cholinergic overload associated with strong inhibitors.

  3. 03D2 / 5-HT1A

    Secondary Predicted Activity

    D2 + 5-HT1A Modulation

    Computational research suggests additional interactions with dopaminergic and serotonergic signaling systems that require experimental validation.

    Predicted binding at D2 and 5-HT1A could contribute to affective and motivational balance alongside cognitive effects. These activities are currently in-silico predictions and are treated as hypotheses pending binding and functional assays.

  4. 04α-ADR

    Research Focus

    α-Adrenergic Activity

    Potential adrenergic interactions would be treated as an important selectivity and safety consideration during development.

    α1 and α2 engagement can affect blood pressure, arousal and noradrenergic tone. This axis is tracked primarily as a selectivity boundary: profiling is intended to characterize and, where required, minimize the interaction.

Status

Where the program stands

GB-101 Synaptiva is an investigational preclinical research program. Described mechanisms include both designed activities and computational predictions that require experimental validation. Nothing on this page constitutes a claim of clinical efficacy or safety.

View the pipeline